Cancer

Home » Cancer » Cancer Prevention & Hereditary Cancer Risk » QuitSmart® + Chantix Study®

QuitSmart® + Chantix Study®

Now participants who enroll in Methodist Hospital’s QuitSmart Smoking Cessation Program will have the option to participate in a varenicline (Chantix) study. Eligible candidates are required to have an evaluation by Jane Theobald, MD, psycho-oncologist. If cleared by Dr. Theobald, participants will receive their first month of the Chantix prescription free from Methodist Estabrook Cancer Center (a $100 value). Participants will be monitored weekly during their first month of use, and then monthly thereafter.

To register or for more information, call the Methodist Hospital QuitSmart coordinator at (402) 354-5237.